公开(公告)号：US20220211762A1

公开(公告)日：2022-07-07

申请号：US17607389

申请日：2020-04-27

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Kyuboem HAN ,  Chun-Hyung KIM ,  Shin-Hye YU ,  Seo-Eun LEE ,  Sang-Min LIM ,  Hahnsun JUNG ,  Kwangmin NA ,  Yoon Mi HAN ,  Jun Young SON ,  Jong-Cheon HA ,  Kyunghee JUNG ,  Young-Cheol KANG ,  Eun-Seo LEE ,  Mi Jin KIM ,  Yong-Soo CHOI ,  Jung Uk HWANG ,  Min Ji LEE ,  Kyuseok KIM ,  Tae Nyoung CHUNG

IPC分类号： A61K35/19 ,  A61K35/28 ,  A61K45/06 ,  A61P31/00

摘要： The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1β, TNF-α and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

公开(公告)号：US20220211754A1

公开(公告)日：2022-07-07

申请号：US17607850

申请日：2020-04-29

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Kyuboem HAN ,  Chun-Hyung KIM ,  Shin-Hye YU ,  Seo-Eun LEE ,  Sang-Min LIM ,  Hahnsun JUNG ,  Kwangmin NA ,  Yoon Mi HAN ,  Jun Young SON ,  Eun Young LEE ,  Jeong Yeon KIM ,  Yeong Wook SONG ,  Jin Chul PAENG ,  Yun Sang LEE ,  Do Won HWANG

IPC分类号： A61K35/12 ,  A61K35/30 ,  A61K35/17 ,  A61K35/33 ,  A61K35/19 ,  A61K35/35 ,  A61K35/28 ,  A61K35/34 ,  A61K35/50 ,  A61K35/52 ,  A61K35/54 ,  A61K35/545

摘要： The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1β, TNF-α, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

公开(公告)号：US20230270780A1

公开(公告)日：2023-08-31

申请号：US18044559

申请日：2021-08-10

申请人： Paean Biotechnology Inc.

发明人： Young-Cheol KANG ,  Kyuboem HAN ,  Sang-Min LIM ,  Hahnsun JUNG ,  Hye Jeong HWANG ,  Junyoung SON

IPC分类号： A61K35/12 ,  A61K9/00 ,  A61K9/08 ,  A61K47/18 ,  A61K47/26

CPC分类号： A61K35/12 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/183 ,  A61K47/26

摘要： Provided is a composition for injection containing isolated mitochondria. More specifically, provided is a liquid composition for injection containing glycine, saccharide, buffer, and mitochondria, and a pharmaceutical composition comprising the liquid composition for injection as an active ingredient. The liquid composition for injection according to the present disclosure is capable of securing the safety of a mitochondrial therapeutic and maintaining the activity of mitochondria, by enhancing the stability of mitochondria for prevention or treatment of mitochondria-related diseases and preventing and inhibiting formation of blood clots in the blood of a subject who is administered with the same. Accordingly, the pharmaceutical composition according to the present disclosure may solve the aggregation that may occur when mitochondria are administered in the body and thus enables to safely and effectively inject mitochondria into the body to be used for the purpose of preventing and treating various diseases caused by mitochondrial dysfunction.